Approved indications
Delstrigo is FDA-approved as a complete regimen for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 35 kg who have no antiretroviral treatment history or who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable regimen with no history of treatment failure and no known substitutions associated with resistance to its components.

Off-label uses
Delstrigo is not commonly used off-label beyond its approved HIV-1 indications; clinicians may individualize use in certain virologically suppressed patients where regimen simplification is desired, provided resistance and comorbidities are carefully reviewed, but high-quality evidence is limited outside labeled populations.

Efficacy expectations
In clinical trials, many treatment-naive patients achieved viral suppression (HIV-1 RNA <50 copies/mL) within about 12–24 weeks, with high rates of suppression maintained through at least 96 weeks when taken as directed. Delstrigo’s effectiveness in reducing viral load and sustaining suppression is generally comparable to other modern once-daily combination regimens, with the advantage of a single-tablet regimen that can support adherence.

Typical dosing
For adults and pediatric patients weighing at least 35 kg, the recommended dose of Delstrigo is one tablet taken orally once daily, with or without food, as a complete regimen; no additional antiretroviral drugs are usually needed.

How to take
Swallow the tablet whole with water; take it at about the same time each day to maintain steady drug levels. Do not take more than one tablet per day unless specifically directed by a healthcare professional.

Special instructions
If you also take certain other medicines (such as rifabutin), your healthcare provider may adjust doses or avoid the combination. Dose adjustments may be needed in significant kidney impairment, and Delstrigo is generally not recommended in severe renal dysfunction or when certain resistance mutations are present.

Missed dose guidance
If a dose is missed and it is within about 12 hours of the usual time, take the missed tablet as soon as remembered and then take the next dose at the regular time; if it is almost time for the next dose, skip the missed dose and resume the regular schedule without doubling doses.

Overdose
In case of overdose, seek emergency medical help or contact a poison control center immediately; provide information about the amount taken and the time of ingestion, and do not take further doses until advised by a healthcare professional.

Common side effects
Common side effects include nausea, headache, dizziness, fatigue, diarrhea, abnormal dreams, and trouble sleeping; these are often mild to moderate and most likely to appear in the first days to weeks of treatment, frequently improving over time.

Serious or rare adverse effects
Serious reactions can include severe liver problems, lactic acidosis, kidney problems (including kidney failure and Fanconi syndrome), decreased bone mineral density, severe skin or allergic reactions, and worsening of hepatitis B after stopping the medicine in people co-infected with HBV; sudden or severe symptoms such as shortness of breath, chest pain, unusual muscle pain, yellowing of the skin or eyes, dark urine, severe rash, or swelling of the face or throat require immediate medical attention.

Warnings and precautions
Use requires caution in people with kidney disease, liver disease (including hepatitis B or C), a history of bone problems, or risk factors for lactic acidosis. In pregnancy, Delstrigo may be used when benefits outweigh risks, but regimen choice should be individualized; breastfeeding is generally not recommended for people with HIV. It is not indicated for children under the body-weight threshold specified in the prescribing information.

Safety compared with similar drugs
Compared with some older non-nucleoside and tenofovir-based regimens, Delstrigo has a relatively favorable side-effect and drug–drug interaction profile, though tenofovir disoproxil fumarate still carries kidney and bone risk and monitoring is important.

Reporting side effects and safety updates
Patients and caregivers can report side effects to the FDA MedWatch program or to their healthcare professional, and updated safety information can be found in the prescribing information and on regulatory health agency websites.

Drug and supplement interactions
Delstrigo can interact with certain prescription drugs, especially those that strongly induce or inhibit liver enzymes involved in doravirine metabolism (for example, rifampin, carbamazepine, phenytoin, St. John’s wort), which can reduce effectiveness or increase side effects; some other antiretrovirals should not be combined with it. Always check with a healthcare professional before starting or stopping any prescription, over-the-counter medicine, or herbal supplement.

Food, alcohol, and procedures
Delstrigo may be taken with or without food, and there are no specific food restrictions, although maintaining overall kidney and bone health is advisable. Moderate alcohol use may be permissible in some patients but should be limited, particularly in those with liver disease. Inform providers that you are taking Delstrigo before surgeries, imaging studies, or other procedures so potential interactions with anesthetics or contrast agents can be reviewed.

Precautions and contraindications
Use is generally avoided with strong enzyme inducers such as rifampin or St. John’s wort, and in patients with known hypersensitivity to any component. Caution is required in patients with significant kidney or liver impairment, chronic hepatitis B infection, osteoporosis, or other risk factors for kidney or bone disease.

Monitoring needs
Regular monitoring typically includes HIV viral load and CD4 count to assess effectiveness, along with kidney function tests, liver enzymes, and sometimes bone health assessments, especially in patients at higher risk; additional tests may be ordered based on other medications or medical conditions.

Q: Is Delstrigo a complete HIV treatment regimen or do I need other HIV medicines with it?
A: Delstrigo is designed as a complete once-daily regimen for many adults and adolescents with HIV-1, so most patients do not need additional antiretroviral drugs unless their clinician identifies specific resistance, comorbidities, or interactions that require a different regimen.

Q: How long does it take for Delstrigo to start working on my viral load?
A: When taken every day as prescribed, many people see a substantial drop in viral load within the first few weeks, and a large proportion reach undetectable levels within about 3–6 months, though the exact timing varies by person and starting viral load.

Q: Can I take Delstrigo with my other daily medicines and vitamins?
A: Many medicines and supplements can be taken with Delstrigo, but some can reduce its effectiveness or increase side effects, so you should always review all prescriptions, over-the-counter drugs, and herbal products with your healthcare professional or pharmacist before combining them.

Q: What if I vomit after taking a dose of Delstrigo?
A: If you vomit within about an hour of taking Delstrigo, contact your healthcare provider or pharmacist for advice, as they may recommend taking another tablet; if vomiting occurs later than that and you feel well, you may usually wait until the next scheduled dose.

Q: Can I stop Delstrigo once my viral load is undetectable?
A: You should not stop Delstrigo or change your HIV regimen without medical guidance, because stopping treatment can allow the virus to rebound, increase the risk of resistance, and raise the chance of transmitting HIV.

Storage
Store Delstrigo tablets at room temperature in the original tightly closed container, away from excess heat and moisture, and out of reach of children and pets.

Disposal
Dispose of unused or expired Delstrigo through a medicine take-back program when possible; if unavailable, follow local guidance for safe disposal and do not flush tablets down the toilet unless specifically instructed.